Brexpiprazole

BreastfeedingGeriatricPediatric
  • TRADE NAME: Rexulti (Otsuka)
  • INDICATIONS: Schizophrenia, major depressive disorder (with antidepressants)
  • CLASS: Antipsychotic
  • HALF-LIFE: 86–91 hours

FDA APPROVAL DATE: 07/10/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Strong or moderate CYP2D6 inhibitors, Strong or moderate CYP3A4 inducers or inhibitors

PREGNANCY CATEGORY: N/A
Neonatal risk in third trimester exposure

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS


See full prescribing information for complete boxed warning.

Our database has 41 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top